Renal phosphate loss in Iraqi chronic myeloid leukemia patients treated by imatinib mesylate

BACKGROUND: The use of BCR-ABL tyrosine kinase inhibitor imatinib mesylate improved outcomes for patients with chronic myeloid leukemia (CML). Hypophosphatemia is found to be associated with imatinib mesylate use; the exact mechanism of this is not clear yet but mostly related to a drug-induced prox...

Full description

Bibliographic Details
Main Authors: Huda A Al-Taee, Azhar K Athab, Ala Ali
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2020-01-01
Series:Iraqi Journal of Hematology
Subjects:
Online Access:http://www.ijhonline.org/article.asp?issn=2072-8069;year=2020;volume=9;issue=2;spage=72;epage=76;aulast=Al-Taee